Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05624554 · ClinicalTrials.gov registry record · Phase 3
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
A Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT05624554 is a Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 300 participants, above the 180-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (67% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT05624554, a Phase 3 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer. Researchers want to know if people who take nemtabrutinib compared to those who take the standard treatments in this study will live longer without their cancer growing, spreading or returning (progression free survival).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Nemtabrutinib
- BIOLOGICAL Rituximab
- DRUG Bendamustine
Study Locations (20)
Other
- Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 ( Site 1319) - Rio de Janeiro
- ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 1308) - São Paulo
- Hospital Paulistano-Americas Oncologia ( Site 1302) - São Paulo
- University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD ( Site 6404) - Plovdiv
- Medical Centre Pratia Clinic EOOD ( Site 6406) - Plovdiv
- UMHAT "Prof. Dr. Stoyan Kirkovich"AD-Clinical Hematology ( Site 6400) - Stara Zagora
- Multriprofile Hospital for Active Treatment "Hristo Botev" ( Site 6402) - Vratsa
Region M. de Santiago
- Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1509) - Santiago
- FALP-UIDO ( Site 1500) - Santiago
- Clínica Inmunocel ( Site 1511) - Santiago
São Paulo
- Hospital Amaral Carvalho-Centro de Pesquisas ( Site 1304) - Jaú
- A. C. Camargo Cancer Center ( Site 1318) - São Paulo
Arkansas
- Highlands Oncology Group ( Site 5205) - Springdale
Florida
- Clermont Oncology Center ( Site 5224) - Clermont
Mississippi
- Hattiesburg Clinic Hematology/Oncology ( Site 5216) - Hattiesburg
Washington
- Medical Oncology Associates, PS ( Site 5206) - Spokane
South Australia
- Royal Adelaide Hospital ( Site 1105) - Adelaide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-03-16 |
| Est. Completion | 2031-03-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05624554
The ClinicalTrials.gov registry entry for NCT05624554 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 180-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (67% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05624554 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Region M. de Santiago, São Paulo.
Frequently Asked Questions
What is clinical trial NCT05624554 about?
NCT05624554 is a clinical study titled "A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)". Researchers are looking for new ways to treat people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are types of blood cancer. Researchers want to know if people who take nemtabrutinib compared to those who take the standard treatments in this study will liv...
What is the current status of trial NCT05624554?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2023-03-16. Estimated completion is 2031-03-17.
What conditions does trial NCT05624554 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma.
What interventions are being tested in trial NCT05624554?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Nemtabrutinib (DRUG), Rituximab (BIOLOGICAL), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT05624554?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05624554 being conducted?
This trial has 20 study locations across Arkansas, Florida, Mississippi, Washington, South Australia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
RECRUITING · Phase 3
-
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
RECRUITING · Phase 3
-
A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
RECRUITING · Phase 3
-
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
RECRUITING · Phase 3
-
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.